Jazz Pharmaceuticals plc

NASDAQ:JAZZ   12:59:59 PM EDT
129.79
-3.43 (-2.58%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)7.96B
Current PE198.29
Forward PE 8.91
2yr Forward PE 7.4
See more stats
Estimates Current Quarter
Revenue$836.36 Million
Adjusted EPS$3.28
See more estimates
10-Day MA$133.18
50-Day MA$150.33
200-Day MA$163.10
See more pivots

Jazz Pharmaceuticals plc Stock, NASDAQ:JAZZ

Waterloo Exchange, Waterloo Road, Dublin, Dublin 4
Ireland
Phone: +353.1.634.7800
Number of Employees: 1940

Description

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.